Transparency Market Research

Asthma Drug Segment Dominated the Overall Asthma and COPD Market at USD 14,509.1 Million

Transparency Market Research Announced Report Title "Asthma and COPD Drug Market - Global Industry Analysis, Market Size, Share, Trends, Growth and Forecasts" And Its Full Database.


Albany, NY -- (SBWIRE) -- 08/31/2015 -- Introduction to Asthma and COPD

Everyone wants to breathe the air of freedom without any major hindrance or respiratory problem. However, in many cases, people suffer from breathing problems that can arise from pneumonia, asthma, emphysema, or chronic obstructive pulmonary disease, also commonly known as (COPD).

Asthma being one of the most common disorders is defined as a respiratory condition that affects the airway system of our body wherein, the tubes that carry the air in and out of the body is inflamed and constricted due to one or more environmental triggers. Asthma is a type of a chronic disease, and if this potentially fatal condition is left untreated, there are chances for the condition to worsen making a person suffer from extreme respiratory problems to breathe the environmental air in any form.

Browse Full Asthma and COPD Drug Market Research Report With Complete TOC @

People who suffer from the asthma attacks have swollen airways' walls that get narrower when irritated causing sensations within their ENT area. This makes it difficult for the person to take in subsequent amount of air for a hassle-free inhale. Likewise, the airways' walls of the patients suffering from COPD are almost similar. Patients suffering from asthma and COPD conditions have airways' walls inflamed with mucus.

Worldwide, over 300 million people suffer from asthma which has subsequently aggravated the drug market to reach a figure worth over $15 billion. Asthma can be treated by drug therapy or by avoiding environmental triggers.

Global Market Size and Share of Asthma and COPD Drug Market

The global asthma and COPD market was worth USD 25,102.3 million in 2010, which is expected to reach USD 26,965.5 million in 2017 along with a CAGR figure of 1.03% over the forecasted period (2010 - 2017).

While for several decades there have been drugs to treat asthma, the present day pharmaceutical companies have manufactured more effective products to treat asthma successively and efficaciously. According to the global research study, the current asthma and COPD market is majorly driven by the rising patient population. However, some other factors such as expiry of drug patents and price erosion of leading drug brands in the market are also considered to be the value-driven factors that will help to expand this market in the next five years.

In 2010, the asthma drug segment dominated the overall asthma and COPD market at USD 14,509.1 million. In the same year, the COPD segment was projected to be worth USD 10,593.2 million and is expected to reach USD 12,619.8 million in 2017.

The latest generation of asthma drugs such as GlaxoSmithKline's Advair and AstraZeneca's Symbicort in the market has superseded the older drugs and medicinal products that were once used to treat asthma and COPD. GlaxoSmithKline, Merck, and AstraZeneca are the current leaders in this industry. However, Symbicort, Advair and Singulair will continue to lead the global asthma and COPD market for the forecast period 2010 – 2017. Advair was once seen as the market leader to treat asthma with USD 7,802 million in 2011, followed by Singulair which was the second largest drug in terms of revenue at UD 5479 million in the same year.

Asthma and COPD are two chronic diseases that are experiencing growing prevalence due to an arrangement of factors including – globally aging population and rise in pollution levels. The chronic obstructive pulmonary disease (COPD) is one of the top five reasons of death and disability in urban countries, as well as the fourth-leading cause of death globally.

China – The biggest market of Asthma and COPD patients

Due to rising growth in urbanization, smoking activities, changing lifestyle, and increasing air pollution, the occurrence of asthma and COPD conditions is sharply rising in China. Over the recent years, the occurrence of asthma symptoms is observed to be higher in the urban areas as compared to the rural regions.

Request For Sample Report:

About Transparency Market Research
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us
Mr. Nachiket Ghumare
Transparency Market Research
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453